QQQ   270.75 (-0.11%)
TSLA   1,485.00 (+0.00%)
BA   173.30 (-0.56%)
QQQ   270.75 (-0.11%)
TSLA   1,485.00 (+0.00%)
BA   173.30 (-0.56%)
QQQ   270.75 (-0.11%)
TSLA   1,485.00 (+0.00%)
BA   173.30 (-0.56%)
QQQ   270.75 (-0.11%)
TSLA   1,485.00 (+0.00%)
BA   173.30 (-0.56%)
Log in

NYSE:PENPenumbra Stock Price, Forecast & News

$236.07
+8.60 (+3.78 %)
(As of 08/6/2020 09:30 AM ET)
Add
Compare
Today's Range
$228.70
Now: $236.07
$237.23
50-Day Range
$167.70
MA: $190.38
$229.48
52-Week Range
$121.80
Now: $236.07
$230.86
Volume196,410 shs
Average Volume233,959 shs
Market Capitalization$8.52 billion
P/E Ratio814.06
Dividend YieldN/A
Beta0.72
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands. It also offers neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400 and Penumbra SMART Coil brands. In addition, the company provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; and detachable embolic coil systems for peripheral embolization under the RUBY Coil brand, as well as microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand. Further, it offers detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand; and aspiration-based thrombectomy systems for peripheral applications under the Indigo System brand, as well as a complementary device for use with RUBY Coil and POD for vessel occlusion under the POD Packing Coil brand. The company sells its products through direct sales organizations and distributors to hospitals in neuro and peripheral vascular markets. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.
Read More
Penumbra logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 3.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.39 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone510-748-3200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$547.41 million
Cash Flow$1.30 per share
Book Value$17.26 per share

Profitability

Net Income$48.46 million

Miscellaneous

Employees2,700
Market Cap$8.52 billion
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$236.07
+8.60 (+3.78 %)
(As of 08/6/2020 09:30 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PEN News and Ratings via Email

Sign-up to receive the latest news and ratings for PEN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Penumbra (NYSE:PEN) Frequently Asked Questions

How has Penumbra's stock been impacted by COVID-19 (Coronavirus)?

Penumbra's stock was trading at $176.86 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PEN shares have increased by 33.5% and is now trading at $236.07.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Penumbra?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Penumbra
.

When is Penumbra's next earnings date?

Penumbra is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Penumbra
.

How were Penumbra's earnings last quarter?

Penumbra Inc (NYSE:PEN) announced its quarterly earnings data on Monday, August, 3rd. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.09. The business earned $105.11 million during the quarter, compared to analysts' expectations of $100.75 million. Penumbra had a net margin of 2.02% and a return on equity of 1.25%. The business's quarterly revenue was down 21.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.27 EPS.
View Penumbra's earnings history
.

What price target have analysts set for PEN?

5 Wall Street analysts have issued 1-year price targets for Penumbra's stock. Their forecasts range from $192.00 to $264.00. On average, they expect Penumbra's share price to reach $231.20 in the next twelve months. This suggests that the stock has a possible downside of 2.1%.
View analysts' price targets for Penumbra
.

Has Penumbra been receiving favorable news coverage?

News articles about PEN stock have been trending negative recently, according to InfoTrie. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Penumbra earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days.
View the latest news about Penumbra
.

Are investors shorting Penumbra?

Penumbra saw a decline in short interest during the month of July. As of July 31st, there was short interest totaling 2,780,000 shares, a decline of 6.1% from the July 15th total of 2,960,000 shares. Based on an average daily trading volume, of 234,800 shares, the short-interest ratio is presently 11.8 days. Currently, 8.3% of the company's stock are sold short.
View Penumbra's Current Options Chain
.

Who are some of Penumbra's key competitors?

What other stocks do shareholders of Penumbra own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Penumbra investors own include NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), AbbVie (ABBV), DexCom (DXCM), Intuitive Surgical (ISRG), Medtronic (MDT), Boeing (BA), salesforce.com (CRM) and Gilead Sciences (GILD).

Who are Penumbra's key executives?

Penumbra's management team includes the following people:
  • Mr. Adam Elsesser, Co Founder, Chairman, CEO & Pres (Age 57)
  • Dr. Arani Bose, Co-Founder, Chief Innovator and Director (Age 57)
  • Mr. Sridhar N. Kosaraju, CFO and Head of Strategy (Age 41)
  • Ms. Lynn Rothman, Chief Bus. Officer and Exec. VP (Age 58)
  • Mr. Daniel Donen Davis, Chief Commercial Officer (Age 41)

What is Penumbra's stock symbol?

Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."

Who are Penumbra's major shareholders?

Penumbra's stock is owned by a variety of institutional and retail investors. Top institutional investors include Ardevora Asset Management LLP (0.79%), First Trust Advisors LP (0.40%), Columbus Circle Investors (0.31%), Principal Financial Group Inc. (0.30%), Redwood Investments LLC (0.22%) and Swiss National Bank (0.21%). Company insiders that own Penumbra stock include Adam Elsesser, Arani Bose, Bridget O'rourke, Coyne David, Daniel Donen Davis, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, Robert D Evans, Sridhar Kosaraju and Thomas Wilder.
View institutional ownership trends for Penumbra
.

Which major investors are selling Penumbra stock?

PEN stock was sold by a variety of institutional investors in the last quarter, including Columbus Circle Investors, Ardevora Asset Management LLP, First Trust Advisors LP, Oak Ridge Investments LLC, WINTON GROUP Ltd, Mission Wealth Management LP, Russell Investments Group Ltd., and Texas Permanent School Fund. Company insiders that have sold Penumbra company stock in the last year include Adam Elsesser, Arani Bose, Bridget O'rourke, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, Sridhar Kosaraju, and Thomas Wilder.
View insider buying and selling activity for Penumbra
.

Which major investors are buying Penumbra stock?

PEN stock was acquired by a variety of institutional investors in the last quarter, including Tiedemann Advisors LLC, Swiss National Bank, SG Americas Securities LLC, Highland Capital Management LLC, Brinker Capital Inc., Principal Financial Group Inc., State of Michigan Retirement System, and Exchange Traded Concepts LLC.
View insider buying and selling activity for Penumbra
.

How do I buy shares of Penumbra?

Shares of PEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Penumbra's stock price today?

One share of PEN stock can currently be purchased for approximately $236.07.

How big of a company is Penumbra?

Penumbra has a market capitalization of $8.52 billion and generates $547.41 million in revenue each year. The company earns $48.46 million in net income (profit) each year or $0.98 on an earnings per share basis. Penumbra employs 2,700 workers across the globe.

What is Penumbra's official website?

The official website for Penumbra is www.penumbrainc.com.

How can I contact Penumbra?

Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The company can be reached via phone at 510-748-3200 or via email at [email protected]

This page was last updated on 8/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.